Skip to main content
Erschienen in: Clinical and Translational Oncology 11/2020

22.04.2020 | Research article

Urinary microRNAs expression in prostate cancer diagnosis: a systematic review

verfasst von: R. M. Paiva, D. A. G. Zauli, B. S. Neto, I. S. Brum

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Circulating microRNAs (miRNAs) have been shown to have the potential as noninvasive diagnosis biomarkers in several types of cancers, including prostate cancer (PCa). Urine-based miRNA biomarkers have been researched as an alternative tool in PCa diagnosis. However, few studies have performed miRNA detection in urine samples from PCa patients, as well as low numbers of miRNAs have been assayed, and there is a lack of standard strategies for validation. In this context, we conducted an in-depth literature review focusing on miRNAs isolated from urine samples that may contribute to the diagnosis of PCa.

Methods

A systematic review was performed searching the PubMed, Lilacs and Cochrane Library databases for articles focused on the value of significantly deregulated miRNAs as biomarkers in PCa patients.

Results

Only 18 primary manuscripts were included in this review, according to the search criteria. Our results suggest that miR-21-5p, miR-141-3p, miR-375 and miR-574-3p should be considered as potential urinary biomarkers for the diagnosis of PCa.

Conclusion

These results suggested that large-scale prospective studies are still needed to validate our findings, using standardized protocols for analysis.
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
Zurück zum Zitat Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol Semin Orig Investig. 2011;29:593–601. Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol Semin Orig Investig. 2011;29:593–601.
3.
Zurück zum Zitat Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care. 2001;17:275–304.PubMedCrossRef Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care. 2001;17:275–304.PubMedCrossRef
4.
Zurück zum Zitat Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002;3:19.PubMedPubMedCentralCrossRef Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002;3:19.PubMedPubMedCentralCrossRef
5.
Zurück zum Zitat Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.PubMedCrossRef Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.PubMedCrossRef
7.
Zurück zum Zitat Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803:1231–43.PubMedCrossRef Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803:1231–43.PubMedCrossRef
8.
Zurück zum Zitat Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs in prostate cancer pathogenesis. Clin Genitourin Cancer. 2015;13:261–70.PubMedCrossRef Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs in prostate cancer pathogenesis. Clin Genitourin Cancer. 2015;13:261–70.PubMedCrossRef
9.
Zurück zum Zitat Esquela-kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRef Esquela-kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRef
10.
Zurück zum Zitat Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMedPubMedCentralCrossRef Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Balacescu O, Dumitrescu RG, Marian C. MicroRNAs role in prostate cancer. Methods Mol Biol. 2018;1856:103–17.PubMedCrossRef Balacescu O, Dumitrescu RG, Marian C. MicroRNAs role in prostate cancer. Methods Mol Biol. 2018;1856:103–17.PubMedCrossRef
12.
Zurück zum Zitat Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16:80.PubMedPubMedCentralCrossRef Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16:80.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–77.PubMedPubMedCentralCrossRef Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–77.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Yin C, Fang C, Weng H, Yuan C, Wang F. Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48:1087–95.PubMedCrossRef Yin C, Fang C, Weng H, Yuan C, Wang F. Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48:1087–95.PubMedCrossRef
16.
Zurück zum Zitat McDonald AC, Vira M, Shen J, Sanda M, Raman JD, Liao J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78:411–8.PubMedCrossRef McDonald AC, Vira M, Shen J, Sanda M, Raman JD, Liao J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78:411–8.PubMedCrossRef
17.
Zurück zum Zitat Souza MF, Kuasne H, Barros-Filho MC, Cilião HL, Marchi FA, Fuganti PE, et al. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE. 2017;12:e0184094.PubMedPubMedCentralCrossRef Souza MF, Kuasne H, Barros-Filho MC, Cilião HL, Marchi FA, Fuganti PE, et al. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE. 2017;12:e0184094.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 2018;4:825–33.PubMedCrossRef Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 2018;4:825–33.PubMedCrossRef
19.
Zurück zum Zitat Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016;115:707–15.PubMedPubMedCentralCrossRef Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016;115:707–15.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep. 2016;13:4549–60.PubMedPubMedCentralCrossRef Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep. 2016;13:4549–60.PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768–74.PubMedPubMedCentralCrossRef Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768–74.PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol. 2014;192:252–9.PubMedCrossRef Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol. 2014;192:252–9.PubMedCrossRef
23.
Zurück zum Zitat Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013;8:e76994.PubMedPubMedCentralCrossRef Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013;8:e76994.PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol. 2015;33:16.e17–e22.CrossRef Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol. 2015;33:16.e17–e22.CrossRef
25.
Zurück zum Zitat Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic. Prostate. 2016;76:68–79.PubMedCrossRef Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic. Prostate. 2016;76:68–79.PubMedCrossRef
26.
Zurück zum Zitat Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 2017;77:573–83.PubMedCrossRef Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 2017;77:573–83.PubMedCrossRef
27.
Zurück zum Zitat Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigoreva AE, Zaporozhchenko IA, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS ONE. 2016;11:e0157566.PubMedPubMedCentralCrossRef Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigoreva AE, Zaporozhchenko IA, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS ONE. 2016;11:e0157566.PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2014;4:370.PubMedPubMedCentralCrossRef Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2014;4:370.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, et al. MiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS ONE. 2014;9:e98675.PubMedPubMedCentralCrossRef Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, et al. MiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS ONE. 2014;9:e98675.PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRef Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRef
31.
Zurück zum Zitat Mekhail SM, Yousef PG, Jackinsky SW, Pasic M, Yousef GM. MiRNA in prostate cancer: new prospects for old challenges. EJIFCC. 2014;25:79–98.PubMedPubMedCentral Mekhail SM, Yousef PG, Jackinsky SW, Pasic M, Yousef GM. MiRNA in prostate cancer: new prospects for old challenges. EJIFCC. 2014;25:79–98.PubMedPubMedCentral
32.
Zurück zum Zitat Shah JS, Soon PS, Marsh DJ. Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS ONE. 2016;11:e0153200.PubMedPubMedCentralCrossRef Shah JS, Soon PS, Marsh DJ. Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS ONE. 2016;11:e0153200.PubMedPubMedCentralCrossRef
33.
Zurück zum Zitat Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:731479.PubMedPubMedCentralCrossRef Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:731479.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Brett SI, Kim Y, Biggs CN, Chin JL, Leong HS. Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:213–20.PubMedCrossRef Brett SI, Kim Y, Biggs CN, Chin JL, Leong HS. Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:213–20.PubMedCrossRef
35.
36.
Zurück zum Zitat Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101:13368–73.PubMedPubMedCentralCrossRef Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101:13368–73.PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Koppers-Lalic D, Hackenberg M, de Menezes R, Misovic B, Wachalska M, Geldof A, et al. Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;7:22566–78.PubMedPubMedCentralCrossRef Koppers-Lalic D, Hackenberg M, de Menezes R, Misovic B, Wachalska M, Geldof A, et al. Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;7:22566–78.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. Prostate. 2017;77:1167–75.PubMedCrossRef Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. Prostate. 2017;77:1167–75.PubMedCrossRef
39.
Zurück zum Zitat Lekchnov EA, Amelina EV, Bryzgunova OE, Zaporozhchenko IA, Konoshenko MY, Yarmoschuk SV, et al. Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. Int J Mol Sci. 2018;19:E4088.PubMedCrossRef Lekchnov EA, Amelina EV, Bryzgunova OE, Zaporozhchenko IA, Konoshenko MY, Yarmoschuk SV, et al. Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. Int J Mol Sci. 2018;19:E4088.PubMedCrossRef
40.
Zurück zum Zitat El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep. 2016;6:19529.PubMedPubMedCentralCrossRef El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep. 2016;6:19529.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Brunet-Vega A, Pericay C, Quílez ME, Ramírez-Lázaro MJ, Calvet X, Lario S. Variability in microRNA recovery from plasma: comparison of five commercial kits. Anal Biochem. 2015;488:28–35.PubMedCrossRef Brunet-Vega A, Pericay C, Quílez ME, Ramírez-Lázaro MJ, Calvet X, Lario S. Variability in microRNA recovery from plasma: comparison of five commercial kits. Anal Biochem. 2015;488:28–35.PubMedCrossRef
42.
Zurück zum Zitat Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16:991–1006.PubMedPubMedCentralCrossRef Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16:991–1006.PubMedPubMedCentralCrossRef
44.
Zurück zum Zitat Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet. 2001;29:365–71.PubMedCrossRef Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet. 2001;29:365–71.PubMedCrossRef
45.
Zurück zum Zitat Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.PubMedCrossRef Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.PubMedCrossRef
46.
Zurück zum Zitat Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. MiR-21-5p, miR-141-3p, and miR-205-5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019;79:88–95.PubMedCrossRef Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. MiR-21-5p, miR-141-3p, and miR-205-5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019;79:88–95.PubMedCrossRef
47.
Zurück zum Zitat Balacescu O, Petrut B, Tudoran O, Feflea D, Balacescu L, Anghel A, et al. Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet? Wiley Interdiscip Rev RNA. 2017;8:e1438.CrossRef Balacescu O, Petrut B, Tudoran O, Feflea D, Balacescu L, Anghel A, et al. Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet? Wiley Interdiscip Rev RNA. 2017;8:e1438.CrossRef
48.
49.
Zurück zum Zitat Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32:583–8.CrossRef Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32:583–8.CrossRef
50.
Zurück zum Zitat Filella X, Foj L. MiRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55:715–36.PubMedCrossRef Filella X, Foj L. MiRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55:715–36.PubMedCrossRef
51.
Zurück zum Zitat Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, Quindós-Varela M, Santamarina-Caínzoz I, Antón-Aparicio LM, et al. MicroARN circulantes en sangre de pacientes con cáncer de próstata. Actas Urológicas Españolas. 2014;38:633–9.PubMedCrossRef Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, Quindós-Varela M, Santamarina-Caínzoz I, Antón-Aparicio LM, et al. MicroARN circulantes en sangre de pacientes con cáncer de próstata. Actas Urológicas Españolas. 2014;38:633–9.PubMedCrossRef
52.
Zurück zum Zitat Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 2019;21:126–44.PubMedCrossRef Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 2019;21:126–44.PubMedCrossRef
53.
Zurück zum Zitat Yang Y, Guo JX, Shao ZQ. MiR-21 targets and inhibits tumor supressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10:87–91.PubMedCrossRef Yang Y, Guo JX, Shao ZQ. MiR-21 targets and inhibits tumor supressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10:87–91.PubMedCrossRef
54.
Zurück zum Zitat Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017;482:1381–6.PubMedCrossRef Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017;482:1381–6.PubMedCrossRef
55.
Zurück zum Zitat Pickl JMA, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, et al. Ago-RIP-Seq identifies polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget. 2016;7:59589–603.PubMedPubMedCentralCrossRef Pickl JMA, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, et al. Ago-RIP-Seq identifies polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget. 2016;7:59589–603.PubMedPubMedCentralCrossRef
56.
Zurück zum Zitat Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2017;36:24–34.PubMedCrossRef Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2017;36:24–34.PubMedCrossRef
57.
Zurück zum Zitat Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16:156.PubMedPubMedCentralCrossRef Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16:156.PubMedPubMedCentralCrossRef
58.
Zurück zum Zitat Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17:E1784.PubMedCrossRef Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17:E1784.PubMedCrossRef
59.
Zurück zum Zitat Wani S, Kaul D, Mavuduru RS, Kakkar N, Bhatia A. Urinary-exosomal miR-2909: a novel pathognomonic trait of prostate cancer severity. J Biotechnol. 2017;259:135–9.PubMedCrossRef Wani S, Kaul D, Mavuduru RS, Kakkar N, Bhatia A. Urinary-exosomal miR-2909: a novel pathognomonic trait of prostate cancer severity. J Biotechnol. 2017;259:135–9.PubMedCrossRef
60.
Zurück zum Zitat Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin Chem Lab Med. 2015;53:1109–18.PubMed Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin Chem Lab Med. 2015;53:1109–18.PubMed
61.
Zurück zum Zitat Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5:182–91.PubMedPubMedCentralCrossRef Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5:182–91.PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Guelfi G, Cochetti G, Stefanetti V, Zampini D, Diverio S, Boni A, et al. Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research. Sci Rep. 2018;8:7111.PubMedPubMedCentralCrossRef Guelfi G, Cochetti G, Stefanetti V, Zampini D, Diverio S, Boni A, et al. Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research. Sci Rep. 2018;8:7111.PubMedPubMedCentralCrossRef
Metadaten
Titel
Urinary microRNAs expression in prostate cancer diagnosis: a systematic review
verfasst von
R. M. Paiva
D. A. G. Zauli
B. S. Neto
I. S. Brum
Publikationsdatum
22.04.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 11/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02349-z

Weitere Artikel der Ausgabe 11/2020

Clinical and Translational Oncology 11/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.